Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Alzheimer's

This page shows the latest Alzheimer's news and features for those working in and with pharma, biotech and healthcare.

Merck and Cerevance to research novel targets in Alzheimer’s disease

Merck and Cerevance to research novel targets in Alzheimer’s disease

The companies will work together to identify novel targets for Alzheimer’s disease. ... We believe we are well-positioned to identify novel targets for neurodegenerative diseases and look forward to collaborating with Merck to potentially bring forward

Latest news

More from news
Approximately 167 fully matching, plus 421 partially matching documents found.

Latest Intelligence

  • Alzheimer’s disease: the search for a cure Alzheimer’s disease: the search for a cure

    Over the past two decades, Alzheimer’s drug discovery has largely focused on targeting the hallmark amyloid protein. ... other than the build-up of the hallmark Alzheimer’s proteins, amyloid and tau.

  • Alzheimer’s: the search for a cure Alzheimer’s: the search for a cure

    Future Alzheimer’s research. Three points of interest critical to future Alzheimer’s research became more crystalised as a result of these studies:. ... Despite their limitations, available outcome scales, such as the Alzheimer’s Disease Assessment

  • The search for treatments for Parkinson’s disease The search for treatments for Parkinson’s disease

    and Alzheimer’s diseases. ... It’s snakes and ladders. “The world is not abandoning neuroscience. It is just recognising that it is tricky and difficult.”.

  • Alzheimer’s: the search for a cure Alzheimer’s: the search for a cure

    Tau is emerging as a target for drug development in Alzheimer’s, as well as other disorders like frontotemporal dementia. ... big diseases in the field, such as Alzheimer’s, is too limited to make near-term success likely.

  • Great expectations: the urgent need for common purpose in Alzheimer’s disease Great expectations: the urgent need for common purpose in Alzheimer’s disease

    By Andrew Harrison. A few years ago, when communicating the phase 3 data of a major trial in Alzheimer’s disease (AD), our prime goal was focused on accuracy of reporting ... Most of us will have experience of family or friends with Alzheimer’s or

More from intelligence
Approximately 9 fully matching, plus 42 partially matching documents found.

Latest appointments

  • Cognite strengthens team with two new additions Cognite strengthens team with two new additions

    She has demonstrated real drive and talent across a wide range of disease areas including oncology, MS, diabetes and Alzheimer’s, making her ideally suited to help build successful breakthrough science

  • Metrion Biosciences establishes scientific advisory board Metrion Biosciences establishes scientific advisory board

    The new board will be chaired by Dr Keith McCullagh, Metrion’s non-executive chairman, and its members will include Dr David Reynolds, chief scientific officer at Alzheimer’s Research UK.

  • J&J’s clinical research neuroscience director joins MedAvante J&J’s clinical research neuroscience director joins MedAvante

    Prior to this, he was medical director, global medical affairs for Janssen's Alzheimer's disease immunotherapy unit from June 2011 to May 2013. ... He also brings extensive experience in psychiatry, neurology and dermatology, making him an ideal addition

  • Asceneuron appoints chief medical officer Asceneuron appoints chief medical officer

    He joins the neurodegenerative diseases specialist from Novartis, where he had served a s vice president of its neuroscience development franchise and therapeutic head for neurodegeneration since 2011. ... Alzheimer's disease.

  • UK Dementia Research Institute names director UK Dementia Research Institute names director

    In his new role, Prof De Strooper will work with the institute's founding partners - the Medical Research Council, Alzheimer's Society and Alzheimer's Research UK - to develop new therapeutics

More from appointments
Approximately 0 fully matching, plus 23 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 4 fully matching, plus 26 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

The communication challenge of helping he next generation to be healthier
As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
Are we losing sight of what the democratisation of healthcare really looks like?
We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
William Kilgallon
How the Royal Society’s EiR programme can help to drive UK innovation
...

Quick links